1714 – National Blood Authority listing for ObizurŪ (susoctocog alfa) for treatment of bleeding episodes with acquired Haemophilia A

Page last updated: 25 July 2023

Application Detail

Description of Medical Service

Susoctocog alfa is a treatment used to replace the missing protein needed for blood clotting (Factor VIII), which is less susceptible to being inhibited by autoantibodies than the patient’s own protein. This allows clotting to occur and assists to stop the bleeding. It also allows for the patient’s protein levels to be measured, to assist with guiding dosing and optimising treatment efficacy and safety.

Description of Medical Condition

Acquired Haemophilia A is a condition where patients present with spontaneous bleeding despite no history of a bleeding disorder. Patients have the required protein needed for blood clotting, but autoantibodies develop to inhibit this normal function.

Reason for Application

Referral from National Blood Authority

Medical Service Type


Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1169 KB)
Application Form (Word 201 KB)

Consultation Survey

Consultation Survey (PDF 660 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Expedited – Bypassing PASC

MSAC Consultation
MSAC consultation input closed Friday, 10 February 2023.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 700 KB)
Public Summary Document (Word 151 KB)

Meetings for this Application


Bypassing PASC


9-10 February 2023


30-31 March 2023